Top Medtech Industry Leadership Highlights SEMDA 2016 Plenary Sessions

By
 In News

The 2016 SEMDA Conference is less than three weeks away! We expect this year’s even to be the best ever, with better programming, more attendees, and more high-quality investors than ever. No doubt the highlight of the event are our plenary speakers, who will offer insights applicable to medtech entrepreneurs, investors and associated service providers across the board.

Suzanne Belinson, Executive Director with the Blue Cross Blue Shield Association, will kick us off on Wednesday morning. The BlueCross BlueShield Association has a long history of leadership in evidence based review. The Evidence Street™, a new web-based platform, takes this history to new levels allowing manufacturers the opportunity to submit materials for consideration, track evidence reviews, and collectively receive Evidence Opinions. The Evidence Street™ platform is designed to represent where the market meets the evidence. Suzanne will give a summary of the Evidence Street platform and share her vision for BCBSA.

The Wednesday lunch keynote will feature Niall Brenan, Chief Data Officer and Director of the Office of Enterprise Data and Analytics (OEDA) with the Centers for Medicare and Medicaid Services. Niall’s talk is titled “Leveraging CMS Data to Accelerate Health System Change” and will focus on CMS’ effort to maximize its data resources for internal and external users through innovative use of new technologies, increased transparency and organizational and culture change. After Niall’s presentation, there will be Question and Answer time moderated by Don May, Executive Vice President for Payment & Healthcare Delivery with AdvaMed.

Our Gala Dinner presentation will be a discussion with Dr. Sam Lynch, Founder and Former CEO of BioMimetic. Dr. Lynch will share his experiences and lessons learned during his time at the helm of BioMimetic in an informal fireside chat discussion with Brian Johnson, Founder of DeviceTalks.  Dr. Lynch founded BioMimetic in 2001 and steered the company from startup to IPO to acquisition by Wright Medical valued at $390 million. The Company successfully developed and gained FDA approval of two drug-device combination products, GEM 21s and Augment Bone Graft, the latter approved in 2015 following an initial rejection in August 2013. With successful approval Augment became the first clinically proven protein therapeutic to come to the U.S. orthopedics market in over a decade. Dr. Lynch is one of, if not the only, person we know that is the discoverer of a medical therapeutic and led the company he founded based on that technology through its entire life cycle from start-up to IPO to trade sale. He currently consults for biomedical clients, including investors and businesses, and serves on the board of Vanderbilt University Medical Center.

Our final speaker will be Dr. Bruce Rosengard, Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies. In his role as Chief Medical Science & Technology Officer with J&J’s Medical Device Companies, Dr. Rosengard will discuss J&J’s efforts to build the medtech pipeline through heavy external collaboration. This model has been applied successfully within J&J’s pharmaceuticals division. The goal is to utilize this model in its medtech businesses with the goal of boosting innovation and growth. Part of that effort can be found in J&J’s innovation centers in San Francisco, Boston, Israel, London and Shanghai. In a recent article in MedCity News, Rosengard said, “Since we’re in these different environments, we can pick and choose among the best partnerships out there. We’re watering and fertilizing the environment to help build an innovation ecosystem that’s really bidirectional.”20150616_135709-IMG_0004 (1)

The anticipation is building. Get in on SEMDA 2016, May 17-19 in Nashville!

Sincerely,
Jason

Jason Rupp, Executive Director, SEMDA

*Photo credit: Glen Stubbe, Minneapolis Star Tribune